The frequency of infection caused by the recently described pathogen Mycobacterium lepromatosis is unknown. Here, we describe the demographics, clinical characteristics, and therapeutic outcomes of five lepromatous leprosy patients suffering from M. lepromatosis infection in Nuevo Léon, Mexico. Diagnosis was facilitated by a new highly specific PCR procedure.
Mycobacterium leprae causes Hansen's disease, or leprosy, a chronic infection transmitted from human to human by close contact and manifests clinically in several forms. Leprosy was recently declared to have been eliminated from most regions of the world (1). Since its original description by Armauer Hansen in 1873, the diagnosis of leprosy has relied on the detection of acid-fast bacilli (AFB) in clinical samples. In 2008, a new etiologic agent, Mycobacterium lepromatosis, was associated with leprosy in the United States (2). It was detected in autopsy specimens from two patients of Mexican ethnicity, using molecular biology techniques. On screening samples from patients attending our dermatology clinic who were diagnosed with Hansen's disease, we detected M. lepromatosis in a diffuse lepromatous leprosy (DLL) case (3) but found no evidence for M. leprae in the biopsy sample. Subsequently, cases of M. lepromatosis infection have been reported in Canada, Singapore, Brazil, and Myanmar (4, 5).In Mexico, the largest study conducted was that of Han et al. (6), and this included 120 samples from patients with various clinical forms of leprosy; 63.2% of the cases harbored M. lepromatosis alone, and 16% were mixed infections in which both M. leprae and M. lepromatosis were present. In all these cases, the bacteria were identified using a PCR assay employing primers for the 16S rRNA gene. The genome sequence of M. lepromatosis was recently obtained (7), and loci present in M. lepromatosis, but absent from M. leprae, were identified, thus enabling a highly specific PCR procedure to be established.In the present work, we screened biopsy specimens from patients currently receiving treatment at our clinic to determine the prevalence of M. lepromatosis, or of mixed infections, using a new specific PCR procedure. A diagnosis was initially made clinically and confirmed by the detection of AFB in Fite-Faraco-stained skin biopsy specimens. For molecular analysis, DNA was extracted from the biopsy specimen and used in PCR assays with primers designed to detect M. leprae (RLEP-7 and RLEP-8) or M. lepromatosis (LPM244-F [5=-GTTCCTCCACCGACAAACAC-3=] and LPM244-R [5=-TTCGTGAGGTACCGGTGAAA-3=]) (7). The pair for M. lepromatosis amplifies a 244-bp fragment from the hemN gene missing in M. leprae (7).A total of 38 patients were analyzed; among them, we observed 5 cases positive for M. lepromatosis (Table 1), constituting 13% of the total cases. Four were from Nuevo León and one from the neighboring state of San Luis Potosi, and none were related. Four presented with lepromatous leprosy, of whom three were diagnosed with DLL and one with nodular lepromatous leprosy (NLL); none of t...